Failure of miltefosine in visceral leishmaniasis is associated with low drug exposureFailure of miltefosine in visceral leishmaniasis is associated with low drug exposure
Institute of Development Policy and Management
Faculty of Pharmaceutical, Biomedical and Veterinary Sciences . Biomedical Sciences
Research group
Department of Biomedical Sciences - other
Institute of Development Policy and Management - other
Publication type
Chicago, Ill.,
Human medicine
Source (journal)
The journal of infectious diseases. - Chicago, Ill.
Target language
English (eng)
Full text (Publishers DOI)
Background. Recent reports indicated high miltefosine treatment failure rates for visceral leishmaniasis (VL) on the Indian subcontinent. To further explore the pharmacological factors associated with these treatment failures, a population pharmacokinetic-pharmacodynamic study was performed to examine the relationship between miltefosine drug exposure and treatment failure in a cohort of Nepalese VL patients. Methods. Miltefosine steady-state blood concentrations at the end of treatment were analyzed using LC-MS/MS. A population pharmacokinetic-pharmacodynamic analysis was performed using non-linear fixed-effects modeling and a logistic regression model. Individual estimates of miltefosine exposure were explored for their relationship with treatment failure. Results. The overall probability of treatment failure was 21%. The time the blood concentration exceeded the threshold of 10x the EC50 of miltefosine (median 30.2 days) was significantly associated with treatment failure: a decrease of this measure of miltefosine exposure with 1 day was associated with a 1.08 times (95% CI 1.01-1.17) increased odds of treatment failure. Conclusions. Achieving sufficient miltefosine exposure is a significant and critical factor for VL treatment success, which urges the evaluation of the recently proposed optimal allometric miltefosine dosing regimen. This study establishes the first evidence for a drug exposure-effect relationship for miltefosine in the treatment of VL.